Page 40 - Haematologica May 2020

N. Curto-Garcia et al.
liferative neoplasms: results of phase II
study SAKK 33/14. Haematologica.
2019;104(4):710-716.
113.Mesa RA, Silver RT, Verstovsek S, et al.
Single agent bevacizumab for myelofibrosis: Results of the myeloproliferative disorders research consortium trial. Haematologica. 2013;98(9):1421-1423.
114. Giles FJ, List AF, Carroll M, et al. PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leuk Res. 2007;31(7):891-897.
115. Hermouet S, Bigot-Corbel E, Gardie B. Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of
ChronicInflammation.MediatorsInflamm.
2015;2015:145293.
116.Baumeister J, Chatain N, Hubrich A, et al.
Implication of Hypoxia-Inducible Factor-1 (HIF-1) As a New Therapeutic Target in JAK2-V617F Positive Myeloproliferative Neoplasms (MPN). Blood. 2018;132(Suppl 1):4318.
117. Xia Y, Choi H-K, Lee K. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem. 2012;49:24-40.
118.Barosi G, Gattoni E, Guglielmelli P, et al. Phase I/II study of single-agent bortezomib for the treatment of patients with myelofi- brosis. Clinical and biological effects of pro- teasome inhibition. Am J Hematol. 2010;85 (8):616-619.
119.MascarenhasJ,SandyL,LuM,etal.Aphase II study of panobinostat in patients with pri- mary myelofibrosis (PMF) and post-poly- cythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). Leuk Res. 2017;53:13-19.
120.Kleppe M, Koche R, Zou L, et al. Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell. 2018;33(1):29- 43.e7.
121. Mascarenhas J, Navada S, Malone A, Rodriguez A, Najfeld V, Hoffman R. Therapeutic options for patients with myelofibrosis in blast phase. Leuk Res. 2010;34(9):1246-1249.
1200
haematologica | 2020; 105(5)